Efficacy of atypical antipsychotics in schizophrenia patients: effects of 5-HTR SNPs.

IF 3.6 3区医学 Q1 PSYCHIATRY

Annals of General Psychiatry Pub Date : 2025-02-18 DOI:10.1186/s12991-025-00547-z

Keying Liu, Bide Zhang, Zhoufangyuan Chen, Fukun Chen, Zexu Li, Yunzhi Gao, Yuechao Zhao, Yihao Liu, Yanlong Wang

{"title":"Efficacy of atypical antipsychotics in schizophrenia patients: effects of 5-HTR SNPs.","authors":"Keying Liu, Bide Zhang, Zhoufangyuan Chen, Fukun Chen, Zexu Li, Yunzhi Gao, Yuechao Zhao, Yihao Liu, Yanlong Wang","doi":"10.1186/s12991-025-00547-z","DOIUrl":null,"url":null,"abstract":"<p><p>The 5-hydroxytryptamine receptor (5-HTR) is a key protein responsible for the effects of 5-hydroxytryptamine (5-HT) and an important target for many antipsychotics. 5-HTR has a high degree of genetic polymorphism, and atypical antipsychotics are 5-HTR antagonists widely used in treating schizophrenia. With the increasing development of medical technology, antipsychotics are being updated rapidly, and their efficacy and safety are being optimised. However, owing to the complexity of patients' genetic polymorphisms and psychiatric disorders, there are still individual differences in clinical efficacy. This article reviews the typing of 5-HTR, a common target of clinical atypical antipsychotics, and the effects of 5-HTR gene single nucleotide polymorphisms (SNPs) on the efficacy of atypical antipsychotics. Specific genotypes of six types of 5-HTR genes are associated with differential responses to atypical antipsychotics, which may help guide the development of individualized clinical treatments for patients with schizophrenia.</p>","PeriodicalId":7942,"journal":{"name":"Annals of General Psychiatry","volume":"24 1","pages":"10"},"PeriodicalIF":3.6000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837449/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of General Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12991-025-00547-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

The 5-hydroxytryptamine receptor (5-HTR) is a key protein responsible for the effects of 5-hydroxytryptamine (5-HT) and an important target for many antipsychotics. 5-HTR has a high degree of genetic polymorphism, and atypical antipsychotics are 5-HTR antagonists widely used in treating schizophrenia. With the increasing development of medical technology, antipsychotics are being updated rapidly, and their efficacy and safety are being optimised. However, owing to the complexity of patients' genetic polymorphisms and psychiatric disorders, there are still individual differences in clinical efficacy. This article reviews the typing of 5-HTR, a common target of clinical atypical antipsychotics, and the effects of 5-HTR gene single nucleotide polymorphisms (SNPs) on the efficacy of atypical antipsychotics. Specific genotypes of six types of 5-HTR genes are associated with differential responses to atypical antipsychotics, which may help guide the development of individualized clinical treatments for patients with schizophrenia.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of General Psychiatry PSYCHIATRY-

CiteScore

6.60

自引率

2.70%

发文量

审稿时长

>12 weeks

期刊介绍： Annals of General Psychiatry considers manuscripts on all aspects of psychiatry, including neuroscience and psychological medicine. Both basic and clinical neuroscience contributions are encouraged. Annals of General Psychiatry emphasizes a biopsychosocial approach to illness and health and strongly supports and follows the principles of evidence-based medicine. As an open access journal, Annals of General Psychiatry facilitates the worldwide distribution of high quality psychiatry and mental health research. The journal considers submissions on a wide range of topics including, but not limited to, psychopharmacology, forensic psychiatry, psychotic disorders, psychiatric genetics, and mood and anxiety disorders.